• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 18, 2014

View Archived Issues

Alkermes launches phase I in MS with eye on Biogen's Tecfidera

Alkermes plc is ramping up a phase I study of ALKS-8700, a small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis. Read More

In biomarkers, moving from star system to team system

For the time being, the promise of biomarkers has, by and large, not been realized. Although it has been recognized for decades that good biomarkers could greatly improve both resource allocation and patient outcomes, very few biomarkers have sufficient clinical utility to be in widespread use. Read More

Developing countries being hit by vaccines shortage backlash

BOGOTA, Colombia – A shortage of pentavalent and hexavalent vaccines that left children in Latin America and Europe exposed to a series of preventable diseases for months may have been resolved, but countries are still trying to fill in the gaps. Read More

Myos, Cloud collaborate to 'muscle in' on new therapeutic category

Myos Corp., which is taking a bifurcated approach in developing products to improve muscle mass, increase mobility and reduce frailty, is going to the "cloud" through a research and development agreement with newco Cloud Pharmaceuticals Inc. Although terms were not disclosed, the partners will focus on identifying and advancing candidates that inhibit targets in the myostatin regulatory pathway and inflammatory mediators associated with sarcopenia and cachexia. Read More

Arsanis' Nagy talks tackling MRSA with MAb cocktail approach

The infectious disease field is in crisis, according to Eszter Nagy, president and CEO of Arsanis Biosciences Inc., an Austro-American biotech that is offering an approach that differs from the typical antibiotic regimen. Read More

News from Washington

In a push for more corporate accountability, Sens. Bob Casey (D-Pa.), Richard Blumenthal (D-Conn.) and Tom Harkin (D-Iowa) introduced the Hide No Harm Act in the Senate this week. The bill would make it a federal crime, punishable by up to five years in prison, for a corporate officer to knowingly allow a dangerous product or service into the market. Read More

In the clinic

Dipexium Pharmaceuticals Inc., of New York, reported that a phase I study testing Locilex (pexiganan acetate cream 1 percent), an antibiotic peptide formulated as a topical cream, in mild infections of diabetic foot ulcers showed the cream was not an irritant. Read More

Stock movers

Read More

Other news to note

Intermune Inc., of Brisbane, Calif., said pirfenidone was granted breakthrough therapy designation by the FDA in idiopathic pulmonary fibrosis (IPF). Read More

Pharma: Other news to note

Helsinn Group, of Lugano, Switzerland, and Chugai Pharma Marketing Ltd., a wholly owned subsidiary of Chugai Pharmaceutical Co. Ltd., of Tokyo, said they inked an agreement for the marketing rights of netupitant-palonosetron fixed-dose combination (NEPA), being evaluated for the prevention of chemotherapy-induced nausea and vomiting. Read More

Pharma: In the clinic

Ipsen SA, of Paris, said the New England Journal of Medicine published clinical results showing that Somatuline Autogel/Somatuline Depot (lanreotide) achieved statistically significant prolongation and progression-free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Read More

Financings

Critical Outcome Technologies Inc. (COTI), of London, Ontario, amended the expiry date of its approximately 3.6 million common share purchase warrants, which were issued as part of a nonbrokered private placement on Jan. 30, 2013, and scheduled to expire July 29. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe